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1. Introduction
Surgical management of melanoma encompasses primary biopsy and complete wide local
excision (WLE) of the tumor, as well as the surgical treatment of metastatic melanoma,
including both cutaneous and internal metastases. The management of a melanoma suspect
lesion starts with the initial biopsy of the lesion. A great variety of techniques can be used for
the biopsy of melanomas, and the choice of the technique is dependent on multiple factors
(patient’s age, strength of clinical suspicion of melanoma, thickness of the tumor, localization,
etc.). Once the clinical diagnosis of melanoma is confirmed histologically, local tumor control
is established by wide local excision. The margins for WLE are determined by the T stage of
the tumor, and are between 0.5-2.0 cm. Certain clinical melanoma types (e.g. lentigo maligna)
require special attention, as the recommended margins can differ from those generally advised
for other melanoma types.
Important surgical procedures include wide local excision with safety margins, sentinel lymph
node biopsy, regional lymph node dissection and reconstruction of defects after melanoma
excision. A plastic surgeon of the appropriate specialty should perform the excision and
reconstruction.
Performing surgery of locoregional and distant metastases depends on various factors.
However, in highly selected patients, complete surgical resection of the metastases may result
in prolonged survival. In addition, combination of surgery with novel immuno-, and targeted
therapies, may result in an even better outcome in the future for patientswith stage IV disease.
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2. Primary treatment of suspicious pigmented lesion/melanoma
Early diagnosis and complete removal of the malignant cells are of paramount importance in
the treatment of malignant melanoma. This usually requires a two-step approach. First,
pigmented or amelanotic lesions suspicious for melanoma should be promptly biopsied and
submitted to pathological evaluation, and second, the tumor should be subsequently excised
with adequate surgical margins. The margins of the final excision are determined with the
tumor characteristics in mind, as determined by the histopathological analysis of the biopsy
specimen. Thus, removal of appropriate biopsy sample containing the fragment with the worst
prognostic characteristics, is of substantial importance. As extensive loss of tissues may
potentially influence the feasibility of further surgical interventions, such as the sentinel lymph
node biopsy, the use of proper biopsy techniques is essential during the primary treatment of
melanoma.
Recommendations regarding the width of the surgical margin of excision are nowadays clearly
defined for primary melanoma, and are based on the histopathological features of the mela‐
noma. These recommendations, however, are sometimes difficult or impossible to follow, like
in the case of specially localized melanomas, or certain melanoma subtypes. This chapter
summarizes the available evidence regarding different biopsy techniques and the surgical
management of primary melanoma.
2.1. Biopsy of melanoma suspect lesions
The primary aim of performing biopsy in the case of a melanoma suspect lesion is to establish
or exclude the diagnosis of melanoma. An additional goal is to ensure accurate pathological
staging of the tumor in order to enable adequate surgical management by performing wide
local excision (WLE). Excisional, incisional and shave biopsy techniques are used in the
surgical treatment of melanoma.
2.1.1. Excisional biopsy
The preferred biopsy technique for most melanomas is excisional biopsy.[1,2] This means that
the entire lesion is removed with an additional 1-3 mm margin of normal-appearing skin.
Wider excisions, however, should be avoided, to permit subsequent lymphatic mapping for
sentinel lymph node biopsy. Generally, the excised tissue sample should contain part of the
subcutaneous fat as well, and should be oriented to aid subsequent histopathological evalua‐
tion. The positioning of the excision also should possibly allow for subsequent wider excisions.
The excisional biopsy technique can be used in most melanomas, when primary closure of the
wound is feasible. Although the lowest frequency of positive margins is reported when
excisional biopsy is used, positive margins and even residual melanoma on WLE do occur.[3]
2.1.2. Incisional biopsy
The reported frequency of excisional biopsy technique used for diagnosing melanoma varies
significantly with centers, countries, and individuals, and ranges between 10 and 86 percent.
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[1,3-6] Thus, in a significant portion of melanoma suspect lesions, a biopsy technique other
than excisional biopsy are used. Even guidelines that emphasize the importance of excisional
biopsy in melanoma management state that incisional biopsy may be appropriate in certain
clinical circumstances. Such clinical scenarios may include cases when excisional biopsy is not
feasible due to the large size or the location (nose, ear, face, palm, and sole) of the lesion,
concerns about cosmesis or low clinical suspicion of melanoma.
In the case of incisional biopsy only a portion of the lesion is removed, either by a punch biopsy
or using a scalpel (Figure 1.a-c). As incisional biopsy specimens contain only part of the lesion,
concerns regarding misdiagnosis, staging inaccuracy or diagnostic uncertainty may arise.
Careful selection of the biopsy site is therefore crucial to ensure that the biopsy best represents
the entire lesion, both in terms of the type and the T stage of the tumor. This is usually achieved
by sampling the thickest, most raised area of the tumor, or the darkest part of flat lesions.
Complex lesions containing multiple suspicious foci may require more than one simultaneous
biopsy sampling. Both in case of punch biopsy and incisional biopsy adequate depth (reaching
to the subcutaneous fat) of the sampling should be guaranteed.
The theory that incisional biopsy, by cutting through the neoplastic tissue, represents an
increased risk for lymphatic or hematologous metastatisation, and thus it should be regarded
as a harmful procedure, has been refuted by several earlier studies.[3,7] Moreover, Molenkamp
et al. reported slightly better survival in patients with residual tumor cells in their re-excision
samples, compared to patients without residual cells in their re-excision specimen.[3] The
authors speculated that immunity against residual tumor cells, triggered by biopsy induced
wound healing, might be responsible for this finding.
2.1.3. Shave biopsy
In the case of shave biopsy a superficial, a few mm deep flat section of the skin is removed
(Figure 1.d). Shave biopsy is ideally performed at the level of the deep dermis, however, the
depth of excision is often compromised with the desire to provide a cosmetically good result.
Shave biopsy of primary melanoma, as it often results in incomplete removal of the tumor and
thus compromises pathological staging of the tumor, is not recommended in most of the cases
for melanoma biopsy. However, if the index of melanoma suspicion is low, shave biopsy may
be performed. When performing shave biopsy in pigmented lesions, deep scoop shave biopsy
is the preferred technique.
2.1.4. The effect of biopsy techniques on staging, prognosis and treatment of melanoma
The biopsy of the pigmented lesion should not only establish or exclude the diagnosis of
melanoma, but also provide information on the T stage of the tumor. Ideally, this initial T stage
will be the same as the one achieved after the wide local excision of the tumor. This will ensure
that the original treatment plan regarding the width of the surgical margin and the requirement
for sentinel lymph node biopsy, does not need subsequent adjustment. As these treatment
parameters are primarily determined by Breslow’s depth of the tumor, achieving appropriate
deep margin sampling is of paramount importance during melanoma biopsy.
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Theoretically, sampling errors may stem from several scenarios (Figure 1.a-d). Tumor depth
determination may be compromised by not representative tissue sampling (Figure 1a), positive
deep biopsy margin (Figure 1b) or not representative tumor depth (Figure 1c). Diagnostic
inaccuracy, as a consequence of inappropriate tumor depth measurement, may (Figure 1b) or
may not (Figure 1c) lead to upstaging after wide local excision. In a recent study, positive deep
margins were found in 12%, 32%, 17% and 24% of cases undergoing excisional, shave, punch
and incisional biopsies, respectively.[4] After wide local excision, tumor depth was more than
the biopsy depth in 44% of the cases with residual tumors in WLE, and resulted in T-stage
reclassification in 22% of cases. Reclassification was necessary in 2%, 7%, 24% and 24% of cases
when the initial diagnosis was established by excisional, shave, punch or incisional biopsy,
respectively. Diagnostic inaccuracy led to subsequent treatment change in 2%, 5%, 18% and
18% of cases when excisional, shave, punch or incisional biopsy, respectively, was used for
initial sampling. Although there is no data regarding the tumor thickness in the individual
biopsy groups, it is likely that shave biopsy was more frequently used for thinner and incisional
techniques for thicker melanomas. This may explain why initial punch and incisional biopsy
so frequently required later reclassification in this study.
Figure 1. Diagnostic inaccuracy arising from different forms of sampling error using incisional (punch) biopsy or
shave biopsy techniques. Inadequate punch biopsy sampling of pigmented lesion (a) may result in non-representative
tissue sampling. Tissue sample is removed from the benign part of the pigmented lesion, while missing the malignant
part leading to false negative diagnosis. Inadequate depth of punch biopsy sampling (b) results in positive deep mar‐
gin on histology. Accurate T stage cannot be established, and histological reevaluation after WLE will result in the up‐
staging of the tumor from T1 to T2. Inadequate assessment of melanoma depth due to failure in sampling the deepest
part of the tumor (c). Accurate T stage cannot be established, however, reevaluation will not result in upstaging. Posi‐
tive deep margin after shave biopsy sampling of melanoma (d). Proper T stage cannot be established, and diagnostic
inaccuracy may result in upstaging after WLE.
It must also be emphasized that a rather substantial part of excised melanomas are clinically
not suspected to be melanoma, and vice versa, in a smaller, but significant portion of pig‐
mented lesions, the clinical diagnosis of melanoma is not confirmed by the histopathological
examination. The mean number of pigmented lesions to be excised to detect one melanoma
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was 29 (range 11-83) in a study among general practitioners in Perth, Australia.[8] Thus, in
cases of clinical uncertainty, shave or incisional biopsies may help to establish early melanoma
diagnosis, and biopsies may also help to avoid unnecessary wide excisions in case of benign
lesions.
Several studies have compared the effect of biopsy techniques on the prognosis of melanoma.
[9-13] While in some studies a decreased survival rate was associated with incisional, shave
or needle aspiration biopsy compared to those who had excisional biopsy, these studies
included either low number of patients or significant age differences among patient groups.
[12,13] Other, more recent studies, involving significantly higher numbers of patients, found
no negative effect of non-radical diagnostic techniques on the survival of melanoma patients.
[10,11] Moreover, Molenkamp et al. reported slightly better survival in patients with residual
tumor cells in their re-excision samples,[3] and speculated that biopsy induced wound healing
may theoretically trigger immunity against residual tumor cells. In summary, incisional
(punch or scalpel) and shave biopsies may be used for the initial diagnosis of melanoma,
although, excisional biopsy, when feasible, is recommended as the first choice.
2.1.5. Biopsy techniques in different melanoma types and special locations
Although, when feasible, excisional biopsy is the recommended technique for initial diagnosis
of melanoma, there are certainly significant differences among melanoma subtypes, which,
consequently, require different surgical approaches. The most critical factors when choosing
the appropriate biopsy technique are clinical estimate of depth and size and localization of the
lesion. Although there are no general rules regarding biopsy techniques for different clinical
types of melanoma, some practical recommendations can be formulated. It must be empha‐
sized as well that in case of lesions requiring amputation of the anatomical unit (e.g. digit or
ear), histological confirmation of the diagnosis of melanoma is necessary before performing
the final procedure.
• Superficial spreading melanomas, when primary closure of the wound is feasible, should be
removed by excisional biopsy. However, these melanomas usually invade only the upper
dermis, which makes them ideal candidates for shave biopsy. In case of large lesions, when
complete excision of the lesion is not feasible, incisional biopsy is the preferred choice.
• Nodular melanomas, on the other hand, are deeply infiltrating lesions with usually smaller
diameter. In most instances, therefore, nodular melanomas may and should be managed by
excisional biopsy.
• Lentigo maligna usually presents clinically as an extensive, several centimeter large lesion on
the head of elderly patients. Due to its size, location, and the frequent uncertainty in the
diagnosis, as well as the advanced age of the patients, lentigo maligna often requires one or
more initial incisional biopsy sampling to establish the diagnosis of melanoma, and to select
subsequent management strategies.
• Acral-lentiginous melanomas frequently pose a diagnostic challenge on first presentation.
Moreover, their size and location commonly makes them impossible to be treated by
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excisional biopsy. Therefore, especially when surgical management involves amputation,
an initial incisional biopsy is essential to confirm the clinical diagnosis of melanoma.
• Ulcerated and/or regressive melanomas should be managed with special attention, as these
clinical features are usually associated with poorer outcome. Furthermore, both ulceration
and regression can interfere with histopathological evaluation, and can obscure the
establishment of proper diagnosis. Therefore, excisional biopsy sampling is highly recom‐
mended in these cases to avoid false negative diagnosis or understaging.
• Melanomas in special anatomical regions (eyelid, ear, nose, genitoanal) usually require
individual approach, as excisional biopsy sampling is often not feasible with primary
wound closure. For that reason, it is recommended that an incisional biopsy is taken before
final management of pigmented lesions in these locations.
2.2. Wide Local Excision (WLE) of malignant melanoma
Once the histopathological examination of the biopsy sample established the diagnosis of
melanoma, the entire tumor should be surgically removed with adequate safety margins from
the surrounding healthy-appearing skin. The wide local excision is intended to provide
adequate surgical control of the tumor spread by removing all tumor cells from the primary
tumor bed and the potential satellite lesions from the immediate vicinity of the tumor.
Additionally, WLE provides tissue samples for the final T staging of melanoma.
2.2.1. General recommendations for surgical margins for wide local excision of melanoma
Current recommendations for surgical management of melanoma are based on randomized
clinical trials completed several years ago.[14-20] The margin of wide local excision depends
on the T stage of the melanoma, which is primarily determined by the depth of tumor invasion
(see Table 1. for staging). While there has been considerable debate regarding the radicality of
surgery, current guidelines recommend 0.5 – 2.0 cm surgical margins (see Table 1. for recom‐
mended surgical margins).[1]
2.2.2. Surgical margins for wide local excision in clinical types and special anatomical regions
Most melanomas on the trunk and the proximal part of the extremities may be surgically
managed according to the generally recommended margins for re-excision. Certain melanoma
types, however, owing to their unique localization (face, acral region of the extremities) or type
(lentigo maligna), require special approach, and allow only compromised excisional margins.
2.2.2.1. Melanoma in situ (lentigo maligna and non lentigo maligna type)
In general, the NCCN guideline recommends 0.5-1.0 mm margins for in situ melanomas.[1]
These recommendations, however, are based on expert consensus, as there are no randomized
prospective studies that have examined the surgical margins for melanoma in situ. Recently
it has been shown that almost all (99%) melanoma in situ lesions are completely removed with
a 0.9 mm margin, and a margin of 0.6 mm provides negative resection margins in 86% of cases.
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[21] Another recent study found that in situ melanoma lesions that were not lentigo maligna
type, were unlikely to recur if completely removed, even with narrow margins (Figure 2.a).[22]
On the other hand, a significantly higher incomplete excision rate was found in the lentigo
maligna group (Figure 2.b), compared with the non-lentigo maligna type in situ melanomas
(29.3% vs. 5.9%, respectively). Thus, the authors propose more aggressive treatment, if
possible, for in situ melanomas of lentigo maligna type.
2.2.2.2. Eyelid melanoma
There is no generally accepted consensus regarding the appropriate surgical margins for eyelid
melanomas. In this melanoma group, guidelines for WLE are impractical, and cannot be used
in the majority of cases. In a recent retrospective study, local, nodal and distant metastases
occurred in 21%, 11% and 4% of 56 cases with eyelid melanomas, respectively.[23] Pathological
margins of >2 mm were associated with increased disease-free survival, compared with
margins ≤2 mm. Lower eyelid melanomas were found to have significantly higher recurrence
rate than upper eyelid tumors.
2.2.2.3. External ear melanoma
Although external ear melanoma had been considered to be a more aggressive type of
melanoma, this hypothesis is not supported by more recent evidence. Histologically, melano‐
mas arising on the external ear are most frequently superficial spreading melanomas (33-46%),
followed almost equally by lentigo maligna (19.6%-26%) and nodular (16-22%) types. While
narrower excisional margins and Mohs surgery are gaining acceptance in the treatment of ear
T classification Thickness(mm)
Ulceration status/
mitoses
Recommended surgical
margin (cm) Remarks
Tis in situ NA 0.5-1.0 0.5 cm on face, neck, hands, feet
1.0 cm if significant residual
pigment near the biopsy site
T1 ≤1.0 a: w/o ulceration
and mitosis <1/mm2
b: with ulceration
or mitoses ≥1/mm2
1.0
T2 1.01-2.00 a: w/o ulceration
b: with ulceration
1.0-2.0
T3 2.01-4.00 a: w/o ulceration
b: with ulceration
2.0
T4 ≥4.00 a: w/o ulceration
b: with ulceration
2.0
Table 1. Summary of T staging and current National Comprehensive Cancer Network (NCCN) recommended wide
local excision margins for melanoma.
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melanoma as well, the use of these techniques are associated with significant (30%) recurrence
rates.[24] Therefore, management should follow standard melanoma treatment recommen‐
dations in external ear melanoma cases, if feasible (Figure 2.c).
2.2.2.4. Mucosal melanoma of the head and neck
Achieving melanoma-free resection margins is often difficult in this melanoma type (Figure
2.d). This may be attributed to the close proximity of critical anatomic structures, the presence
of satellite formation, multifocality, angiolymphatic invasion, and submucosal spread, which
are common features in oral cavity and sinonasal melanoma. The 2-year and 5-year survival
rates for mucosal melanoma of the head and neck are 54% and 32%, respectively. Taking into
account the high recurrence rate in this melanoma subtype, even apparently localized lesions
may require radical surgery with planned reconstruction.[25,26]
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Figure 2. Melanomas in special anatomical regions require individual surgical approach. In case of in situ melanoma
not lentigo maligna type (a), a 5-6 mm surgical margin is sufficient to ensure clear resection margins. In case of lentigo
maligna type in situ melanomas (b), a wider, 10 mm margin is recommended, if feasible. Management of external ear
melanomas (c) should follow standard melanoma treatment recommendations, if feasible. Mucosal melanomas of the
head and neck region (d) require radical surgery with planned reconstruction in most cases. For mucosal melanoma of
the female genitalia (e) wide excision with a 1-2 cm margin is recommended. Melanoma of the glans, preputium or
urethra (f) wide local excision or penectomy provides effective local control.
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2.2.2.5. Mucosal melanoma of the female genitalia
Although 70% of patients present with clinically localized disease, the overall prognosis of this
melanoma type is poor. Surgical management of vulvar melanoma (Figure 2.e) consist of wide
excision with a 1-cm margin for melanomas with a thickness of <1 mm, and a 2-cm margin for
thicker lesions.[27,28]
2.2.2.6. Mucosal melanoma of the male genitalia
Melanoma of the glans, preputium or urethra is certainly an uncommon entity. Therefore,
standard recommendations are not available for the management of this subtype of melanoma.
Partial penectomy or WLE provided effective local control for low stage penile (Figure 2.f) or
urethral melanomas and all scrotal lesions.[29]
2.2.2.7. Anorectal melanoma
Because of the rarity and the advanced stage at which most patients present, a standard surgical
intervention has not been established to date for anorectal melanoma. Usually, wide local
excision (with negative margin) is the preferred surgical management in most patients.
Extensive disease that is not amenable to local excision, may require abdominoperineal
resection.[30]
2.3. Surgical techniques
2.3.1. Neck and face
The face is an important area because it encompasses the eyes, nose, mouth and it is in
proximity to the ears. The surgical radicality of extension must often be compromised to avoid
injury to these structures. These structures limit the excision margins for surgical treatment of
melanomas occurring on the face. In the management of cutaneous melanoma the first step is
the wide local excision.
The first goal is to treat the cancer with maximal protection of function and aesthetics. We need
take notice of the size and the localization of the defect, what kind of tissues are missing (bone,
muscle, fat, skin, cartilage, etc.), the base of the wound, the acceptable functional impairment,
the morbidity of the donor area, the moveable area around the defect, the history of the patient
(previous operation or irradiation) and the expectations of the patient too. Ideally incisions
should be within the relaxed skin tension lines (RSTL) or parallel to them, so the scars will be
functionally and aesthetically superior. The RSTL is a complex interaction of the external and
internal factors, which contains the skin as well.
If there is a melanoma on the neck, middle or lower area of the face, we can perform an elliptical
excision parallel to the RSTL with a 3 to 5 mm safety border, undermining the surrounding
area and closing the wound primarily.[17] If the tumor size is bigger we need to prepare local
flaps to cover the defect. Local flaps' blood supply are very reliable, random pattern from the
surrounding tissues or axial pattern from a named source artery. The laxity, quality and texture
Surgery and Staging of Melanoma
http://dx.doi.org/10.5772/59471
89
of the surrounding skin is the best to prepare local flaps and it is the nearest approach to the
defect’s skin.
If the size of the defect is too big and there is no possibility for local flaps,skin grafting can be
performed. There are split-thickness and full-thickness skin grafting. The split-thickness skin
is0.25-0.75 mm thick, the procedure is simple, fast, and not demanding. The donor area heals
spontaneously and is fit to be used again as a donor area, although the graft may contract and
become hypo-or hyperpigmented. The full-thickness skin is 0.8-1.1 mm thick, it rarely contracts
and/or gets pigmented, it is more resistant against external cues compared to split-thickness
grafts, and the subcutaneous layer may regenerate. On the other hand, this surgical technique
ismore demanding for the patient, and it requires a good blood supply of therecipient area,
which limits the size of the graft. Lastly, the donor area need to be sutured /closed primarily.
Recommended flaps are: rotational facial flaps, bilobed flaps, transpositonal flaps, V-Y
advancement flaps (Figure 3.). It is uncommon to use distant flaps on the face except for some
cases, when there is not enough skin in the surrounding areas, due to irradiation or previous
operations.
 
 
 
 
 
 
 
 
a)  b)  c) 
Figure 3. Removal of extensive melanoma from the face and reconstruction with combined local flaps. Melanoma (lenti‐
go maligna type) on the face. Note markings of planned flaps (a). Extensive tissue defect after excision of melanoma with
surgical margins. Reconstruction with combined local flaps (b). Good cosmetical result on 10th postoperative day (c).
2.3.2. Eye
After primary melanoma excision the choice of repair depends on the size and location of the
defect, surrounding tissue mobility, degree of vascular compromise, extent of lamella loss, skin
texture and color match. It is not common to excise and primarily close the wounds around
the eyes.[31] In general it is done, if the size of the melanoma is very small, the melanoma is
in situ, there is a sufficient skin laxity, or the patient's general health status does not permit
more intensive surgical intervention. In the periocular region a 5 mm margin of excision for
thin eyelid melanomas is recommended.[32,33] Care must be taken to avoid placing too much
tension on the eyelid. If the defect involves one third of the eyelid margins, we can perform
pentagonal wedge closure after the excision.
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We have to pay attention to the canthal regions and the lower eyelid to avoid their injuries,
leading to dryness and ectropium. We should also pay attention to the eyebrows and try to
reconstruct them.
In this region primarily we perform local flaps and skin grafting or cartilage grafting to cover
the defects after melanoma excision. The local flaps can be skin, skin-subcutaneous and skin-
muscles flaps from the surrounding area, where the laxity, quality and texture are the best
suited to cover these defects. Their blood supply can show random pattern from the subcuta‐
neous layer or axial pattern from a named source artery. In these cases it is advisable to do
cantopexy to prevent ectropium evolution.
Recommended  flaps  are:  V-Y  advancement  flap,  Tenzel  and  Mustarde  rotation  flaps,
Romboid-Limberg  transpositional  flaps,  Median  and  Paramedian  forehead  flaps  and
Glabellar flap.[31,33]
Full-thickness skin graft is used in this region to minimize scaring and pigmentation. It protects
against extrinsic factors and the subcutaneous layer may regenerate. Disadvantages of full-
thickness skin grafting include demanding surgery, the need for good blood supply in the
recipient area and the need for suturing in the donor area. The size of this graft is also limited
(Figure 4.).
If the tumor involves the tarsal plates and after the excision of the melanoma a tarsal defect
develops, auricular or nasal free cartilage graft can be used to cover the defect. Generally, the
cartilage graft can be covered with a local flap to reconstruct the total eyelid layers. In these
cases composite grafts may be used as well, which contain skin, cartilage and, if necessary,
conjunctiva.
Occasionally, if the patient’s general health status is poor, it is acceptable in the medial canthal
area to leave the defect open, and let it heal by second-intention. Adequate wound manage‐
ment and dressing should be applied to help the granulation and epithelisation. Another use
of second-intention healing is to delay skin grafting. After granulation the skin graft procedure
can be performed.[31,33]
 
 
 
 
 
 
 
 
a)  b) 
Figure 4. Full-thickness skin grafting for the reconstruction of lower eyelid defect after excision of melanoma. Lower
eyelid defect (a) and full-thickness skin graft covering of the defect (b).
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2.3.3. Nose
The nose is a three-layered structure of a skin and fibrofatty covering, a bony and cartilaginous
framework and an inner lining of vestibular skin and nasal mucosa. Nasal defect may involve
these layers alone or in combination.[34,35] The nose is divided into topographic subunits, as
tip, dorsum, sidewalls, alar lobules, soft triangles and columella.[34,35] A wide range of
techniques including defect and subunit reconstruction – using simple as well as more complex
flap and multistaged procedures – must be in the surgeon's armamentarium. When a defect
involves greater than 50% of a subunit, replacement of the entire subunit should be considered.
We can perform primary wound closure after elliptical excision with undermining the
surrounding area only on the dorsal region if the size of the tumor is not too large and the skin
is loose. Second-intention healing is good only for superficial wounds on concave surfaces.[34]
If the tumor size is bigger we can use local flaps from the middle face and the frontal region.
(Figure 5. and 6.) The nasal tip, columella and alar regions are more difficult, and primary
closure is usually not possible. Instead we use local flaps, skin grafting and composite grafting
in these regions. The advantages of local flaps over skin grafts include better contour, color
and texture match and less scar contracture. The most common local flap is the nasolabial flap,
while the forehead flap remains the workhorse for major nasal reconstruction with numerous
modifications.[34] Some others are the dorsonasal flap, glabellar flap, advancement flap from
the middle face, and flaps from the upper perioral region. These local flaps are useful for defects
of about 2 cm or less. If the tumor is large enough to require a tip and alar nose amputation,
we can use reconstructive surgical methods or prosthetic devices. Full-thickness skin grafting
is easy to perform and it is useful in the reconstruction of superficial defects in the areas of the
tip and alar lobules (Figure 7.). On the other hand, it may heal with a contrasting flattened and
shiny appearance.[34,35] The term composite graft means that skin and cartilage are grafted
together from the conchal region, helical rim or helical root.
2.3.4. Ear
On the ear after wide excision, which includes skin and subcutaneous tissue removing,
primary closure is usually not performed. There are many options for the reconstruction of
aurical defects including direct closure, second-intention healing, full thickness skin grafts and
local flaps.[36,37] The defects of the posterior wall of the ear, where the skin is more abundant
and loose, can often be closed primarily. If the defect is in the central and anterior region with
intact cartilage, most defects will do well by second intention healing or full thickness skin
grafting.[37] If the defect involves the cartilage the most common surgical procedure is wedge
excision, which means excising the skin and cartilage together in a V or W form. After these
excisions we should reconstruct the cartilage and then the skin. If larger excisions are necessary,
we need to use local flaps, which are from the earlobe, pre-and retroauricular regions. These
flaps iclude direct advancement flap, rotational flaps, transposition and subcutaneous island
flaps. If more than one third of the ear is involved by the tumor, we need to perform partial
amputation. If the tumor is in an advanced stage, it may be necessary to amputate the whole
ear. Amputation requires more complex reconstructive surgical methods to restore the ear or
prosthetic devices can be used.
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2.3.5. Mouth and perioral region
Melanomas in the perioral regions are not common. The tumor can involve the skin, the oral
orbicular muscle and the mucosal layer alone or together.[37] In this region we should pay
Figure 5. Glabellar flap for the reconstruction of a defect on the dorsum of the nose after wide excision of melanoma.
Extensive melanoma on the dorsum of the nose (a). The defect and preparing glabellar flap (b). Suturing the flap (c)
and postoperative results 3 weeks after operation (d).
Figure 6. Forehead flap for the resonstruction of nasal and glabellar defect after melanoma excision. Melanoma on the nose
and glabellar region (a). After ecxision and performing forehead flap (b) Suturing the flap. Good cosmetical result (c).
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attention to protect the muscular-, sensorial-, and the closing function of the mouth, the
adequate oral access for eating and to the use of dentures, to the symmetry, the upper/lower
lip ratio and the quality of scars.[37] After tumor excision, if the defect is less than one half of
the lip width, we can use primary wound closure after undermining the surrounding layers.
Primary closure offers the best aesthetic result and should be prioritized. In the upper lip we
can perform wedge excision while in the lower lip W-shape excision is used. In cases of large
tumor size the defect can be covered by local skin-, and skin-mucosal flaps originating from
the perioral region or from the lips and the inner surface of the mouth. The ideal donor areas
for labial reconstruction are the remaining labial tissue and the opposing lip.[37] The lip is
elastic and can be elongated, which is a very useful for reconstruction.
Recommended local flaps are: V-Y advancement flap, Rotational flap, Nasolabial flap,
Forehead flap, Abby flap, Estlander flap, Karapandzic flap (Figure 8.).
2.3.6. Digits
The skin of the hand and toe is specialized and structurally unique, balancing the need for
sensing, mobility for complex motor skills on the hand, durability to withstand wear and tear
on the toe.[38] Earlier melanomas arising on the skin and/or nail bed of the digits were
mostfrequently managed with amputation at the proximal joint from the tumor. Recently
tissue- sparing excision is performed increasingly.[38] When excising melanomas on the toes,
amputations should be limited to preserve as much length and function of the digit as possible
without compromising the necessary safety border. It requires a more conservative surgery,
wide excision and only partial resection of the affected phalanx.[38] The excision is done in
the subcutaneous layer and on the fingertip, the entire nail complex needs to be removed. In
these cases the defect can be covered with a local flap, like V-Y advancement flap, or we can
use local flaps from the neighboring digits. If the bone is not directly involved it is not necessary
to remove the total phalanx or metacarpus or metatarsus, since the removal of bone in these
localisations does not have oncological benefit (Figure 9.).
Figure 7. Split-thickness skin grafting for the reconstruction of extensive defect on the tip of the nose after excision of
melanoma. Melanoma involving the tip and alar lobules of the nose (a-b) Split-thickness skin graft covering of the de‐
fect (c).
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Figure 9. Surgical management of amelanotic melanoma on the toe. Melanoma present on the distal phalanx of the toe
(a). Amputation at the distal phalanx (b). Suturing of the wound (c).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a)  b) 
c)  d) 
Figure 8. Reconstruction of facial defect with local flap after removal of melanoma. Large defect in the nasolabial re‐
gion after melanoma excision (a). Preparing the local flap (b). Closing the wound with sutures (c). Good postoperative
result 2 weeks after the operation (d).
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2.3.7. Interdigital spaces
Melanomas arising between the digits is difficult to treat. Covering to these defects can be done
with full thickness skin grafts and local flaps. It may be necessary to remove the phalanx and
metacarpuses and/or metatarsuses depending on the progression of the tumor.
2.3.8. Hand and foot
Acral lentiginous melanoma tends to be diagnosed at later stages due to medical diagnostic
mistakes and patients’ poor attention to lesions arising on extremities.[38] The reconstruction
of the defects after melanoma excision on the dorsal or plantar region of the hand is challeng‐
ing. Generally we can use full thickness skin grafts or local flaps and we should pay attention
to retaining function. First, it is important to cover the joints, tendons and bones. If the defect
is large we can perform distal flaps with microsurgical techniques. It is important to mind the
weight-bearing regions of the foot, because reconstructing these defects requires a flap from
the adjacent area or a free flap with microvascular anastomoses that contain adequate soft
tissue to cover the defect and to supply the function too.
3. Surgery of locoregional recurrence of melanoma
Locoregional recurrence can occur as regional nodal disease or as satellite or in-transit
metastases.
In-transit metastases are locoregional relapses found between the primary melanoma and the
draining lymphatic basin. By definition lesions that occur more than 2 cm from the primary
melanoma are termed in-transit metastases. The ones that are located closer (≤ 2 cm) are
regarded as satellite lesions (Figure 10). The risk factors for the development of in-transit
metastases include lymph node involvement and was confirmed as the most important
prognostic factor by Weide et al.[39] Furthermore the risk of local recurrence increases
significantly as the thickness of the primary melanoma increases and with the presence of
ulceration.[15,39] Both satellite and in-transit metastases are regarded as stage IIIB (without
regional nodal metastases) or stage IIIC (with regional nodal metastases) disease by the 2009
American Joint Committee on Cancer staging system and are associated with worse prognosis
than local recurrence.[40] Patient with locoregional recurrences should undergo staging
procedures (e.g. PET, CT scans) to rule out presence of distant metastatic disease. If there is no
evidence of extraregional disease, the treatment strategies for in-transit metastatic disease
depend on the size, number and location of the lesions.
In case of solitar lesion or limited disease surgical excision of the metastases with histologically
negative margins is the adequate treatment. The precise width of surgical margin is not
determined. The resection should be with generous margin depending on the anatomic site
involved. Multifocal metastases within a circumscribed area may be resected en-bloc. Primary
closure is prefered if possible, however skin grafting or flaps may be done for skin coverege.
In patients, who have surgical resectable in-tranist metastases and have not had a lymphane‐
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dectomy previously a sentinel lymph node biopsy (SLNB) may be considered.[41,42] Some
authors recommend performing SLNB even for patients who had undergone SLN biopsy
earlier or lymph node dissection suggesting a potential benefit for proper staging and for
administering the adequate therapy.[43,44]
In the presence of multiple, inoperable, locoregional cutaneous metastases on the extremity
isolated limb perfusion (ILP) should be considered.[45,46] A systematic review of twenty two
studies, including 2 018 patients[47] who had isolated limb perfusion concluded that the
median complete response rate to ILP was of 58.20%, with a median overall response rate of
90.35%. Amputation for extensive regional recurrence is rarely indicated, as patients in such
cases have a high risk of development of metastases in distant organs and no survival benefit
can be achived.
For refractory-, recurrent and for anatomically unresectable lesions intralesional (interferon,
interleukin-2) or topical (imiquimod, diphencyprone) therapy, cryosurgery, electrochemo‐
therapy, laser-, radio-, and systemic therapy may also be an effective treatment opition.[48-51]
Electrochemotherapy combines inravenous or intralesional cytotoxic drug, most commonly
cisplatin or belomycin and intralesional electric pulses (Figure 11.). The electric pulse creates
cell membrane poration resulting in a better penetration of the chemotherapeutic agent.[52,53]
A study has reported a 72% objective response rate of the total of 54 lesions treated with
electrochemotherapy.[53] However, superiority of one over the other has not been proven and
the choice of the method depends on individual factors.
Patients suspicious for regional lymphnode recurrence should have a fine needle biopsy to
confirm the diagnosis and a workup (PET CT or CT scans) to rule out distant metastases. Then
lymphadenectomy should be performed in patients who did not have one or the lymphnode
disscetion was uncompleted. For patients who have undergone previous lymphadenectomy,
excision of the recurrent tumor is still indicated, if feasible. In this case the marking of the
lymphnodes by ultrasound prior the surgery makes the surgeon’s job easier. In patients with
recurrent disease limited to the regional lymph node basin, completion lymphadenectomy
offers the best potentially curative treatment option and can provide excellent long-term
survival for selected patients.[54]
Figure 10. Satelitte metastases (red arrows) around primary melanoma (a) and multiple cutaneous and subcutaneous
in transit metastases on the lower leg (b).
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4. Surgery of stage IV disease
Metastatic melanoma has a poor prognosis and a median survival of 6-10 months depending
on the site of metastasis.[40] These patients are classified as stage IV according to the American
Joint Committee on Cancer (AJCC 2009) staging manual and seperated into three groups (Table
2.). Stage IV patients with M1a disease have higher survival rates than patients with lung
metastases (M1b), who have a better prognosis than those with M1c disease with or without
elevated lactate dehydrogenase serum levels (LDH).[55]
M classification Site of distant metastases LDH level
M1a Metastases of the skin, subcutis or lymph nodes beyond regional lymph
nodes
normal
M1b Lung metastases normal
M1c Distant metastases at other location or
Distant metastases at any location with elevated serum levels of LDH
normal
elevated
Table 2. M classification of distant metastases in melanoma according to AJCC 2009.
Currently there is no gold standard care for treatment of stage IV disease. The therapeutic
landscape for melanoma is rapidly changing. The first novel agent showing overall survival
benefit in unresectable stage III or metastatic melanoma was an anti-CTLA4 blocking mono‐
clonal antibody (ipilimumab) approved by the FDA in 2011.[56] Since then target therapies
have been approved for the treatment of metastatic melanoma (BRAF inhibitors: dabrafenib,
vemurafenib, MEK inhibitor: trametinib).[57-59] Moreover new immun (e.g. PD-1 inhibitors)
and target therapies are on their way. The impact of these drugs on survival rates are clear and
promising, but surgery of distant metastases could increase this rate.
Figure 11. Electrochemoterapy (bleomycin) of multiple cutaneous and subcutaneous melanoma metastases. Before (a)
and 10 days after (b) therapy. Photos courtesy of Erika Kis MD, PhD, Department of Dermatology and Allergology,
University of Szeged, Hungary.
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Numerous studies, mainly retrospective, showed that patients in whom complete surgical
excision of metastases was carried out have a 5-year survival rate of 15–28 % vs. 5-10% in
patients who received systemic therapy alone.[60-64] The prospective trial of the Southwest
Oncology Group showed a median overall survival of 21 months (overall survival at 3 and 4
years were 36% and 31% respectively) in 64 patients whose metastases had been completely
resected. The majority of the patients had one disease site (n=50) and skin and soft tissue sites
were present in more than 50% of the cases. The authors concluded that aggressive surgical
therapy with follow up adjuvant therapy can be an appropriate cure for these selected patients.
[65] International MMAIT-IV trial further supported the role of surgery for stage IV melanoma.
In this prospective trial patients who had undergone complete resection of their metatstatic
disease were treated with two types of immunotherapy. The 5-year survival was 40–45%.[66]
The Multicenter Selective Lymphadenectomy Trial (MSLT-I) also suggested that patients with
complete resection exhibit an improved survival compared to patients receiving systemic
therapy alone, regardless of site and number of metastases.[67]
Despite that these data are persuasive for surgery in patients with distant metastases, surgery
is rarley used in stage IV melanoma except for palliation. Many oncologists believe that once
melanoma has spread to a distant site, surgery is not helpful because patients already have
occult micrometastases and circulating tumor cells. In the report of Koyanagi et al[68,69] 52%
of stage IV patients had detectable circulating tumor cells. However the presence of tumor
cells in the blood do not obviously generate metastatic lesions. Most of stage IV melanoma
patients at first have disease progression in one organ and the number of metastases in the site
can vary.
The advantage of surgical resection of metastatic melanoma is that it may delay disease
progression by interrupting the metastatic cascade associated with hematogenous seeding of
cells to other sites.[70,71] Surgical resection also decreases tumor burden thus reducing tumor-
induced immunosuppression. Metastases greater than 2 cm are eradicated easier with surgery
than with systemic treatments.[72] In addition, surgical resection has less side-effects than
systemic therapeutic agents.
The recent development of imaging techniques has led to more accurate detection of metasta‐
ses (size of 5-10mm), aiding surgeons in improved delineation of the extent of the disease and
planing for the operation. In line with this development in surgical techniques, anesthesia and
intensive supportive care have reduced operative mortality and morbidity rate even for
multiple metastectomy.[71] It is evident that appropriate patient selection is essential for a
good outcome.
Surgery in metastatic diseases is most effective in patients with small number of metastases
and/or few metastatic organ sites.[73] Based on the MSLT-I study and Wevers et al, the percent
of stage IV patients eligible for surgery can range widely from more than half to only 22%.[67,
74] In deciding about surgery, one should consider underlying co-morbidities, performance
status and life expectany. If no survival benefit and/or advantage in quality of life can be
achieved with surgical metastectomy, it may be disregarded. It has been shown by numerous
studies that complete (R0) resection is associated with a better survial and in all cases com‐
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pletness should be strained by the surgeon.[75-78] Further prognostic factors are prolonged
disease-free survival and a tumour-volume doubling time of >60 days.[73,79,80] (Table 3.).
• Feasibility of complete surgical resection (R0)
• Number of metastases
• Site of metastases
• Tumor doubling time
• Disease free interval
• Other therapy modalities
• Acceptable functional deficit
• Co-morbidities
Table 3. Factors to consider prior to surgical resection in stage IV melanoma
Multiple disease sites are not a contraindication to surgical resection but all of the factors
mentioned above should be considered before procedure. Reccurent disease can be treated
with repeated metastectomy.[81-83] Ollila et al points out that prolonged disease-free interval
prior to recurrence and complete surgical metastasectomy of the recurrence were the two most
important prognostic factors for survival after recurrence.
In the case of large tumor masses, when surgery can not be carried out, effective systemic
treatment prior to surgery is advisable in order to treat the initially unresectable disease.
Neoadjuvant setting has been successfully applied in several solid tumors (e.g. breats, head
and neck cancer) but it has not been used in advanced cutaneous melanoma, because no
effective systemic treatments were available for this disease. The presence of new systemic
therapies (biological and target) may change this. Several case reports have shown the
beneficial effects of BRAF inhibitors. Patients with unresectable bulky disease regained
surgical suitabilty after taking the drug for a couple of months[84-86] (Figure 12).
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Figure 12. Neoadjuvant BRAFi in the treatment of melanoma. The 52 year-old patient with unknown primary melano‐
ma and inoperable metastases in the left axillary region (a). BRAF inhibitor (vemurafenib) was initiated. After 3
months of BRAF inhibitor treatment the tumor almost completly regressed (b). Subsequently, the patient underwent
surgery for the remnant disease (c).
Melanoma – Current Clinical Management and Future Therapeutics100
In contrast to BRAF inhibitors, ipilimumab seems to be a less effective agent in neoadjuvant
setting because of its mechanism of action and relatively slow pattern of time response.
However the surgical excision of lesions that are resistant to treatment with ipilimumab may
improve outcomes for some patients. Other immuntherapies are in development (PD-1
inhibitors) which show an earlier tumor response compared to ipilimumab.[87] Overall,
surgical resection of metastatic lesion in highly selected patients appears to offer a survival
advantage over systemic treatment modalities alone. The decision for surgery of stage IV
melanoma patients should be discussed at an interdisciplinary tumor board. After complete
metastectomy, adjuvant therapy may be indicated as melanoma is likely to recur. Surgical
resection should be considered more often than it is currently practiced, since the combined
advances in imaging techniques and promising novel systemic agents can improve patients’
quality of life and clinical outcomes.
4.1. Surgery of distant skin, soft tissue and lymphnode metastases (Stage IV M1a)
Almost 40% of patients with stage IV melanoma have M1a disease.[88] Median survival of
patients in this group is 18-40 months. Skin and soft tissue metastases are usually associated
with a better prognosis than distant lymph node disease (Figure 13.). Positive prognostic
factors for M1a disease are fewer lesions, longer disease-free interval, and smaller size of
tumors.[61] Skin and soft tissue metastases should be resected as soon as possible before the
metastases becomes large and, if applicable, with wide margins (2 cm). In case of lymphnode
metastases regional lymphnode dissection is performed (for details see section on lymph node
dissection). Factors to consider prior to surgical resection in stage IV melanoma are summar‐
ized in Table 3. Complete surgical resection of M1a disease can promote survival up to 60
months, even after recurrence.[81] Metastases can ulcerate causing pain, bleeding, infection,
and decreased quality of life. Surgical resection for palliation may be indicated in these
situations.
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Figure 13. Multiple distant soft tissue metastases (a) and multiple distant skin metastases (b).
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4.2. Surgery of pulmonary metastases (Stage IV M1b)
The lung is the most typical site of visceral metastases (40%) for melanoma. Pulmonary
metastases are associated with a longer survival than metastases to other visceral sites.[40] A
growing number of studies have shown that pulmonary metastectomy improves survival
[89-96] (Table 4). Tafra et al reported that of 984 melanoma patients with lung metastases, the
106 patients that underwent metastectomy had better 5 year survival than patients treated with
non-surgical methods (27% vs. 3%, respectively).[79] Chua et al conducted a large single center
study with 1737 patients.[89] 292 patients had surgery for lung metastases and the 5-year
survival for this patient group was 38%.
According to the various reports, factors predictive of improved survival are: ability to achieve
a complete resection, prolonged disease-free interval (>36 months), 2 or fewer pulmonary
nodules,[89-91] size of the largest metastasis <2 cm, prior response to chemotherapy/immu‐
notherapy, and male sex.[92] While the disease may recurr, most of the data demonstrate that
long term survival can be achieved with repeated metastectomy (in cases of extra-thoracic
lesions also) in suitable patients.[91]
The presence of multiple and even bilateral pulmonary nodules is not a contraindication to
surgery.[89,97] Interestingly, hilar or mediastinal lymph node involvement did not have an
effect on survival.[93] In most cases pulmonary metastectomy involves wedge resection and
segmentectomy with occasional indication for lobectomy.
Author Number of patientsundergoing surgery Median OS (months) 5 year survival (%)
Andrews et al[91] 86 35 33
Chua et al[89] 292 23 34
Leo et al[93] 282 19 22
Neuman et al[94] 26 40 29
Ollila et al[61] 45 23.1 15.6
Petersen et al[90] 318 19 21
Schunan et al[92] 30 18.3 35.1
Tafra et al[79] 106 23 27
Younes et al[96] 48 32 36
OS: overall survival
Table 4. Studies of pulmonary metastectomy in patients with lung metastases from melanoma
As mentioned earlier, patient selection in Stage IV disease is very important. Tumor doubling
time (TDT), an index calculated on the basis of tumour growth rate as detected on the chest
radiographs, is one of the major factors predictive of survival and should be used as a
consideration in the decision of whether or not to operate.[80] Patients undergoing surgical
managment of lung metastases should have pulmonary function and clinical condition
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suitable for the operation, controlled primary lesion, metastases that appeared technically
resectable on diagnostic imaging, and preoperative biopsy consistent with melanoma.
The spread of advanced imaging techniques (CT, PET) contribute to the earlier detection of
melanoma metastases and give a more precise preoperative image of the location, thus aiding
the accurate selection of surgery candidates (Figure 14.).
 
 
 
 
 
 
 
 
 
a)  b) 
Figure 14. Solitary pulmonary metastases in a 40 year-old patient (red arrow). b. Post surgical scarring at the site of the
metastases (blue arrow).
Upper aerodigestive tract metastases of melanoma are extremily rare. The patients are usually
symptomatic with hemoptysis or cough. Treatments with approriate aggressive multimodal
therapies are needed in such cases (metastectomy, segmental resection, laser excision, external
beam radiation).[98-100]
In conclusions, findings are suggestive that pulmonary metastectomy for carefully selected
patients warrant a favourable outcome.
4.3. Surgery of visceral metastases
4.3.1. Liver metastases (Stage IV M1c)
Liver metastases can occur both in cases of cutaneous and/or ocular melanoma. It is important
to distinguish them, as in metastastic ocular melanoma the liver is the predominant metastatic
site (89% of cases) and often the first and only site of metastases.[100,101] In contrast, cutaneous
melanoma metastases can occur in the lungs, lymph nodes, brain and soft tissue. Only few
patients develop liver (15%-20%) and bowel metastases.[102,103] The difference in metastatic
presentation is most likely driven by the absence of lymphatics in the uveal tract, therefore
melanoma spreads hematogenously.[104]
Studies evaluating the role of surgery in the treatment of hepatic metastases from melanoma
are mainly retrospective case series from single institutions. Some of these studies included
non-surgical (chemotherapy, best supportive care etc) comparator arm, while others did not
have a control group.[76-78,105-108] (Table 5.)
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The comparative studies showed a longer median overall survival in patients who underwent
hepatic resection compared to non-surgical treatment in both ocular and cutaneous melano‐
mas. Overall survival was 2-4 months for patients with unresected hepatic metastases versus
28 months for those with completly resected liver metastases.[78] A recent metaanalysis of five
studies also revealed a significant improvment in overall survival after surgery compared to
non-surgical procedures.[109] The majority of noncomparative studies also reported benefit
from resection of metastases.[66,75,110-114]
All studies observed that R0 resection was associated with longer overall survival than R1 or
R2 surgery.[75-78]
Author Melanoma type Number of patients Median OS(months) 5 year survival (%)
Adam et al[110] Cutaneous and ocular 1452 19 21
Caralt et al[117] Cutaneous and ocular NR 26.3 NR
Chua et al[115] Cutaneous and ocular 23 21 NR
de Ridder et al[75] Ocular, cutanous and
unknown
32 29 3
Faries et al[107] Cutaneous and ocular 1078 24.8 30
Frenkel et al[76] Ocular 74 23 NR
Groeschl et al[111] NR NR 39 36
Herman et al[118] Cutaneous and ocular 367 22 NR
Kim et al[119] Cutaneous and GI tract NR 9.5 4
Kodjikian et al[116] Ocular 63 20.5 24
Mariani et al[77] Ocular 798 23.0 NR
Marshall et al[105] Ocular 188 24.0 NR
Pawlik et al[114] Cutaneous and ocular 40 29.4 21 for ocular
Pilati et al[66] Cutaneous and ocular 36 15 NR
Piperno-Neumann et
al[108]
Ocular 470 21 NR
Ripley et al[112] Cutaneous and ocular 539 36 53
Rivoire et al[106] Ocular 63 25 NR
Rose et al[78] Cutaneous 1750 28 29
Ryu et al[113] Cutaneous and ocular 33 29 42
OS: overall survival; NR: not reported
Table 5. Studies of hepatic resection in patients with liver metastases from melanoma
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The outcome of surgery is also influenced by the number of metastases, length of disease-free
interval and limited disease distribution.[78,115,116] However, eligibility for surgery upon the
extent of disease and the number of metastases varied in the studies. In the Kodjikian
study[116], the cut-off number for resection liver metastases was 10 or less lesions.
Recurrence rates following hepatic resection in the studies ranged between 72% to 75%.
[78,111] All in all the hepatic resection for malignant melanoma is a safe operation.
60-day mortality rates were recorded in some reviews at 1.9% and 2.3% and postoperative
complications after metastectomy occured in 15% to 20% of cases.[78,111]
In the treatment of hepatic metastases, systemic and /or non-surgical therapies can be applied
in the form of adjuvant or neoadjuvant settings that supplement surgical resection. There are
no clear data yet to determine the most efficacious time for the administration of systemic
therapy secondary to surgery. Pawlik et al found that patients who had received adjuvant
systemic therapy prior the hepatic resection had increased survival compared to patients
having resection alone.[114] Adam et al reported increased survival in patients responsive to
neoadjuvant chemotherapy.[110]
The data mentioned above indicate that both ocular and cutaneous metastatic melanoma
patients with liver metastases benefit from surgery. To achieve this outcome, accurate patient
selection is crucial. Only patients with limited disease/metastases who can be rendered
surgically free of disease should be considered as candidates for hepatic resection. For patients
with unresectable metastatic melanoma, systemic and /or regional (hepatic intra-arterial
chemotherapy, hepatic arterial embolization, isolated/percutaneous hepatic perfusion)
therapies should be taken into consideration.
4.3.2. Gastrointestinal metastases (Stage IV M1c)
Gastrointestinal (GI) tract is an uncommon metastatic site for melanoma malignum occuring
in only 2-5% of patients. However, more than a quarter of patients with melanoma at autopsy
revealed GI metastases.[120,121] Patients with metastases to the GI are often symptomatic with
pain (29–64%), obstruction (27%), bleeding (27%), palpable mass (12%) or weight loss (9%).
[122] In addition, the high incidence of metastases of melanoma in the small intestine has been
recently assigned to the presence of functionally active chemokine CCR9 on melanoma cells
that facilitate metastases to the small bowel.[123] In a large number of cases palliative surgery
is needed to alleviate bleeding and /or obstruction. Looking at the survival benefit of surgery,
some studies found significantly improved survival in patients who underwent surgery and
had a complete resection.[121,124,125] Ollila et al. reported a 5-year survival rate of 41% after
complete resection.[121]
In conclusion, metastatic melanoma of the gastrointestinal tract is very rare, but should be
suspected in any patient with a history of cutaneous melanoma and new gastrointestinal
symptoms. Surgical interventions for symptomatic patients with melanoma of the gastroin‐
testinal tract significantly relieve pain and improve quality of life and may confer a survival
advantage.
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Figure 15. Duodenal melanoma metastasis.
4.3.3. Metastases to the spleen, the pancreas, or the adrenal glands (Stage IV M1c)
Isolated metastases to the spleen, pancreas or the adrenal glands are extremely rare. Few
reports have demonstrated that surgical resection improves the 5-year survival.[62,126]
Analysis of patients with solitary metastases to the adrenal glands yielded median survival
times of 60 months.[127] In the study of Wood et al, sixty patients underwent adrenalectomy,
hepatectomy, splenectomy, or pancreatectomy for melanoma metastases. The reported 5-year
survival in the group after complete resection was 24%, whereas in the incomplete resection
group, there were no 5-year survivors.[62,126]
4.4. Surgery of brain metastases (Stage IV M1c)
Metastatic disease to the brain is a frequent manifestation of melanoma with cerebral meta‐
stases accounting for 20-54% of deaths from melanoma.[128] It is associated with significant
morbidity and mortality and poor prognosis. The median survival upon diagnosis of the
cranial metastases is approximately 4 months.[129] Non-systemic treatment options are
surgery, and stereotactic or palliative whole-brain radiotherapy.[130,131]
Usually patients present with symptoms such as seizures, vertigo, nausea, and vision altera‐
tion. In patients with good performance status and controlled primary disease, the surgical
resection of solitary cerebral metastases is preferred. Positive prognostic factors in cases of
brain metastases are younger age, good performance status, lack of neurologic symptoms, lack
of extracranial disease and single focus of disease. Surgery might also be indicated for palliative
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reasons. If the solitary lesion is unresectable due to localization or extracranial disease, the
determination of BRAF status is essential, since the efficacy of BRAF inhibitor dabrafenib in
cerebral metastatic disease has been shown.[132] If no mutation is detected in BRAF, ipilimu‐
mab might be a treatment option[133] (for details see chapter ‘Treatment of Brain metastases’).
 
 
 
 
 
 
 
a)  b) 
Figure 16. Pre-operative CT scan with multiple melanoma metastases. Brain metastases are indicated with red arrows
(a). Post surgical CT scan (b).
4.5. Bone metastases (Stage IV M1c)
Skelatal metastases are present in 5-17% of stage IV patients and have a poor prognosis. [134]
Colman et al conducted the largest retrospective analysis of melanoma patients with bone
metastases.[135] The study compared the survival rate of the group of patients who underwent
surgery with wide resection of metastases with the group who received other surgery or were
treated without operation. The observed 1-year overall survival rate in the resection group
was twice as high as that of matched historical controls (50.0 vs. 24.8%). They found that overall
survival may be improved in carefully selected patients where all known macroscopic tumor
can be resected.[134-137]
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